Immuvac (also known as MIP)*
Candidate Overview
Sponsor / Lead Developer: Indian Council of Medical Research
Development partner(s): Cadila Pharmaceuticals
Primary Indication: Prevention of TB disease
Target Population(s): Adolescents and Adults
Clinical Trials
COMPLETED TRIALS |
|
| Registry Number | CTRI/2019/01/017026 |
| Clinical Trial Phase | Phase 3 |
| Clinical Trial Sponsor | Indian Council of Medical Research (ICMR) |
| Primary endpoint(s) for this clinical trial | Prevention of active TB disease |
| Target population(s) for clinical trial | Adults |
| Adolescents | |